Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inyta

- PMLiVE

NICE wants more evidence on skin damage technologies

But ‘spray-on-skin’ and clothes to prevent ulcers can still be used on NHS

- PMLiVE

NICE backs GSK drug for leukaemia

Arzerra on course for NHS use in blood cancer

- PMLiVE

Novo Nordisk’s Klaus Henning Jensen on trends in medical affairs

PMLiVE speaks to the head of clinical, medical and regulatory for Novo in the UK and Ireland

- PMLiVE

NICE backs Boehringer’s blood clot treatment Pradaxa

Draft DVT and PE guidance puts it on course to catch up with Bayer's Xarelto

- PMLiVE

Pfizer gets FDA nod for meningitis vaccine Trumenba

Ahead of Novartis’ rival drug Bexsero

- PMLiVE

Bayer’s Xarelto wins another NICE recommendation

Deemed cost-effective use of NHS resources to prevent blood clots following a heart attack

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

- PMLiVE

Pressure put on Roche to cut Kadcyla’s UK price

30,000 people sign petition to help make the breast cancer drug available on the NHS

- PMLiVE

FDA votes to keep severe warning on Pfizer’s Chantix

Will not relax anti-smoking drug's side effect warning

National Institute for Health and Care Excellence NICE logo

NICE working to tackle antimicrobial resistance

Two guidelines in development to improve NHS use of antibiotic drugs

- PMLiVE

Pfizer’s palbociclib on track for early 2015 launch

Good news for the highly anticipated breast cancer drug

National Institute for Health and Care Excellence NICE logo

NICE publishes its first medicines optimisation guidance

Draft guidelines encourage patient-centred care and improved NHS communications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links